Cambridge Investment Research Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$100K	Buy	22,380 +300	+1%	+$1.4K	﹤0.01%	3793
2025 Q4	$121K	Sell	22,080 -1,610	-7%	-$7.82K	﹤0.01%	3679
2025 Q3	$77K	Hold	23,690	–	–	﹤0.01%	3617
2025 Q2	$55K	Buy	23,690 +200	+0.9%	+$435	﹤0.01%	3535
2025 Q1	$33K	Hold	23,490	–	–	﹤0.01%	3431
2024 Q4	$41K	Sell	23,490 -15	-0.1%	-$31	﹤0.01%	3390
2024 Q3	$47K	Buy	23,505 +7,000	+42%	+$15.4K	﹤0.01%	3336
2024 Q2	$37K	Sell	16,505 -785	-5%	-$2.28K	﹤0.01%	3241
2024 Q1	$50K	Buy	+17,290	New	+$36K	﹤0.01%	3215

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Cambridge Investment Research Advisors's TSHA Position: Q1 2026 in Review

Cambridge Investment Research Advisors increased its Taysha Gene Therapies (TSHA) stake by 1.4% in Q1 2026, buying an estimated $1.4K and bringing the position to 22,380 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #3793.

Cambridge Investment Research Advisors first reported a position in TSHA in Q1 2024 and has held it in 9 quarters since. The position peaked at $121K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

Cambridge Investment Research Advisors held 22,380 shares of Taysha Gene Therapies worth $100K as of Q1 2026.
Cambridge Investment Research Advisors bought 300 Taysha Gene Therapies shares in Q1 2026, an estimated $1.4K.
Taysha Gene Therapies made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #3793 holding.
Cambridge Investment Research Advisors first reported a position in Taysha Gene Therapies in Q1 2024 and has held it in 9 quarters since.
Cambridge Investment Research Advisors's Taysha Gene Therapies position peaked at $121K in Q4 2025.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.